Countries Request a quote
Wolverine — Alphagenics vial
Regenerative · Skin and Beauty

Wolverine

BPC-157 + TB-500

Combination of research peptides in tissue recovery

Components2
Total20mg
Available presentations
Spray format
Quote via WhatsApp Quick guide Research protocol Spray protocol View evidence Reconstitution calculator Physician login

About Wolverine

Wolverine combines BPC-157 and TB-500, two peptides studied mostly in animal models of soft-tissue injury.

BPC-157 has been associated with angiogenesis, with VEGFR2 activation, and with tendon fibroblast migration. Two molecules are sold under the name TB-500: the synthetic N-acetylated 17-23 fragment of thymosin β4 (Ac-LKKTETQ, short chain), which corresponds to its actin-binding domain, and full-length 43-amino-acid thymosin β4 (long chain); the form present in each lot is stated on its certificate of analysis. Most published data on thymosin β4 come from the full-length protein, and each finding states which molecule was studied. In the only published study of the combination that was found (rats with Achilles tendon repair), the combination showed no added benefit over either peptide alone.

Quick guide · 5 key points

Wolverine: BPC-157 and TB-500 together

Wolverine combines BPC-157 and TB-500 (short-chain fragment or full-length thymosin β4, depending on the lot), studied mostly in animal models of tissue injury. Five points from the research.

View research protocolProtocol (PDF) Open guide (PDF) Download guide
  1. 1

    Two peptides, two lines of research

    BPC-157 has been associated with tendon fibroblast migration and VEGFR2 activation (new vessel formation). TB-500, depending on the lot, is the Ac-LKKTETQ fragment (short chain) or full-length thymosin β4 (long chain). Almost all the evidence is for each component on its own.1,2,3

    BPC-157Fibroblast migration (FAK-paxillin) and new vessel formation (VEGFR2).
    TB-500Ac-LKKTETQ fragment (actin-binding domain) or full-length thymosin β4, depending on the lot.
    2 pathwaysDifferent proposed mechanisms for each peptide
  2. 2

    BPC-157: Achilles tendon in rats

    In rats with a transected Achilles tendon, BPC-157 has been associated with better functional, biomechanical and histological recovery, with higher load to failure and better collagen formation than in controls.4

    14 daysTendon follow-up in the rat transection model
  3. 3

    Short-chain TB-500 (fragment)

    In aged mice, the synthetic peptide LKKTETQ (short-chain TB-500 without acetylation) has been associated with dermal wound repair comparable to that of full-length thymosin β4. In human serum in vitro and in rats, short-chain TB-500 was metabolized into shorter fragments; in fibroblasts, only the metabolite Ac-LKKTE showed significant wound closure versus control.5,6

    Ac-LKKTEActive short-chain TB-500 metabolite in fibroblasts (in vitro)
  4. 4

    The combination, tested in rats

    In 32 rats with Achilles tendon repair, TB-500 (described as synthetic thymosin β4, form not stated) was associated with better histological tendon organization and higher load to failure at 4 weeks; BPC-157 showed numerically better scores, without significance for the total scores. The combination showed no added benefit over either peptide alone.7

    Not additiveEffect of the blend vs. each peptide alone, in rats
  5. 5

    Human evidence is minimal

    In an uncontrolled retrospective series, 3 of 4 patients who received BPC-157 and thymosin β4 (TB4, form not specified) in the knee reported pain relief. A systematic review found no clinical safety data for BPC-157. Full-length intravenous thymosin β4 was well tolerated in phase 1 (40 healthy volunteers); no clinical trials with the fragment were found.8,9,10

    4patients given BPC-157 + TB4 in the published human series
References
  1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PMID 21030672
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
  3. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID 23084823
  4. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PMID 14554208
  5. Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PMID 12581423
  6. Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. PMID 38382158
  7. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
  8. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  9. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949
  10. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. PMID 20536472

Components per vial

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

BPC-157

10 mg
G1E2P3P4P5G6K7P8A9D10D11A12G13L14V15
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
CAS number
137525-51-0
PubChem CID
9941957
Length
15 aa

TB-500 (Ac-LKKTETQ / Tβ4)

10 mg
Length
Depends on the lot (see certificate of analysis): Ac-LKKTETQ fragment, short chain (7 aa; C38H68N10O14; 889.0 g/mol), or full-length thymosin β4, long chain (43 aa; C212H350N56O78S; 4963.4 g/mol)

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Preclinical

    BPC-157: in a rat Achilles tendon transection model it has been associated with better functional, biomechanical and histological recovery.

    Staresinic M et al. J Orthop Res. 2003;21:976-983 · PMID 14554208
  2. In vitro

    BPC-157: in tendon fibroblasts it has shown increased cell migration, likely mediated by the FAK-paxillin pathway.

    Chang CH et al. J Appl Physiol (1985). 2011;110:774-780 · PMID 21030672
  3. Preclinical

    TB-500 short chain (LKKTETQ fragment): in aged mice, the synthetic heptapeptide LKKTETQ (the sequence of short-chain TB-500, without the N-terminal acetylation), which reproduces the actin-binding domain of thymosin β4, has been associated with dermal wound repair comparable to that of full-length thymosin β4.

    Philp D et al. Wound Repair Regen. 2003;11:19-24 · PMID 12581423
  4. Preclinical

    BPC-157 + TB-500 (form not specified): in 32 rats with Achilles tendon repair, TB-500 (a commercial product the authors describe as synthetic thymosin β4, without stating whether it was the short-chain fragment or the full-length protein) has been associated with higher maximum load to failure and better histological scores at 4 weeks; BPC-157 showed numerical improvements without significance in total scores, and the combination showed no added benefit over either peptide alone.

    Biçer O et al. Jt Dis Relat Surg. 2026;37:822-837 · PMID 42542926
  5. Preclinical

    TB-500 short chain (Ac-LKKTETQ): in human serum in vitro and in rats, TB-500 was metabolized into shorter fragments (in rats, mainly Ac-LK); in fibroblasts, only the metabolite Ac-LKKTE showed significant wound-closure activity versus control, and the authors suggest that the activity attributed to TB-500 may be due to this metabolite.

    Rahaman KA et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033 · PMID 38382158

More in Regenerative · Skin and Beauty

GHK-CuGLOWKLOWSNAP-8